Our News

Pharmazac launches the new product Apregalin® (pregabalin) for the treatment of peripheral and central neuropathic pain in adults, for epilepsy as adjunctive therapy in adults with […]

Pharmazac has just launched the new product  Vasitimb (ezetimibe + simvastatin) for the prevention of cardiovascular events, for hypercholesterlaemia and the Homozygous Familial Hypercholesterolaemia. Vasitimb is indicated […]

Pharmazac has enriched its product portfolio with the new brand Calcium Folinate/Pharmazac,  an injectable solution 200mg/20ml Bt x 1 vial x20ml for intravenous or intramuscular use. Calcium Folinate/Pharmazac is the […]

Pharmazac launches Abelfiz (aripiprazole) in 10mg, 15mg and 30mg hard tablets for the treatment of schizophrenia in adults and adolescents aged 15 years and older. Abelfiz […]

Pharmazac announces that its state-of-the-art Research and Development Lab at its headquarters received by the Greek Ministry of Health a GMP manufacturing license (clinical batches) for […]

Pharmazac is the official partner for Greece for the multinational companies Sintetica and Rokitan .  

Pharmazac launches the first rosuvastatin generic in the Greek Pharmaceutical Market. Rosuvastatin is available in boxes of 14 and 30 film coated tablets of 5mg, 10mg, […]

Pharmazac was awarded the Salus Index 2016 Active Business Awards prize for its innovation in research and development of plant derived pharmaceutical products, pharmaceutical combinations and […]